OakChart

Foghorn Therapeutics Inc

FHTXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.09+0.19 (10.00%)
2026-11-11 22:22 CET
Market cap
112.83 USD m
Revenue, TTM
112.13 USD m
Net income, TTM
9.42 USD m
Free cash flow, TTM
-83.68 USD m
EPS diluted, TTM
0.03
P/E
67.20
Compare

Price

FHTX against its 20, 50 and 200-day averages
2050200beat
2.004.006.006.7M13.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FHTXclose 2.0920-day 2.0150-day 2.90200-day 4.552.0952w high52w low

72.5% under the 52-week high of 7.61 on 20 Aug 2026. 52-week low 1.79 on 1 Oct 2026. Last 15 sessions, 27.0% high to low

Volume 0.96× normal · the line is the 50-bar volume average

Profile

FHTX
52-week range, 5% of the way up
1.797.61

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Watertown, MA.

IndexRUT
Employees106
IPOOct 23, 2020
Beta3.21
ATR, 14d0.20
Rel volume0.96
Short float7.12%
Insider own46.74%
Inst own48.07%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap125.32M
Enterprise Value12.97M
Income9.42M
Sales112.13M
Book/sh-0.23
Cash/sh2.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees106
IPOOct 23, 2020

Ratios

P/E67.20
Forward P/E-
PEG-
P/S1.12
P/B-
P/C0.80
P/FCF-
EV/EBITDA1.25
EV/Sales0.12
Quick Ratio4.24
Current Ratio4.24
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)0.03
EPS next Y-0.99
EPS next Q-0.27
EPS this Y93.03%
EPS next Y-1101.62%
EPS next 5Y7.74%
EPS past 3/5Y23.34% 8.80%
Sales past 3/5Y17.14% 135.14%
EPS Y/Y TTM103.69%
Sales Y/Y TTM357.33%
EPS Q/Q418.66%
Sales Q/Q924.69%
EarningsNov 09 BMO
EPS/Sales Surpr.439.56% 1077.13%

Ownership

Insider Own46.74%
Insider Trans0.00%
Inst Own48.07%
Inst Trans1.35%
ROA4.76%
ROE-
ROIC36.24%
Gross Margin98.72%
Oper. Margin7.97%
Profit Margin8.40%
SMA203.89%
SMA50-28.03%
SMA200-54.07%
Trades-

Technical

Shs Outstand59.96M
Shs Float31.63M
Short Float7.12%
Short Ratio2.86
Short Interest2.25M
52W High7.61 -72.54%
52W Low1.79 16.76%
Volatility11.05% 7.32%
ATR (14)0.20
RSI (14)42.12
Beta3.21
Rel Volume0.96
Avg Volume787.60K
Volume759,754

Performance

Perf Week-0.48%
Perf Month12.97%
Perf Quarter-67.80%
Perf Half Y-49.88%
Perf YTD-61.30%
Perf Year-52.93%
Perf 3Y-35.29%
Perf 5Y-84.90%
Perf 10Y-
Recom2.00
Target Price5.00
Prev Close1.90
Price2.09
Change %10.00%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 13, 2026DowngradeEEvercore ISIOutperform → In-line$3+43.5%
Oct 02, 2026DowngradeWWedbushOutperform → Neutral$2-4.3%
Oct 02, 2026DowngradeTTD CowenBuy → Hold
Oct 02, 2026DowngradeBBTIG ResearchBuy → Neutral
Feb 17, 2026ResumedJJefferiesBuy$12+474.2%
Dec 18, 2025InitiatedBBTIG ResearchBuy$11+426.3%
Nov 07, 2025InitiatedGGuggenheimBuy$12+474.2%
Sep 17, 2025ResumedRB. Riley SecuritiesBuy$10+378.5%
Apr 23, 2025InitiatedCCitizens JMPMkt Outperform$9+330.6%
Jan 30, 2025InitiatedRB. Riley SecuritiesBuy$10+378.5%

Peers

Mkt cap
TickerCompanyMkt cap
PRLDPrelude Therapeutics Inc301.66M
CCCCC4 Therapeutics Inc379.51M
ARVNArvinas Inc452.51M
GLUEMonte Rosa Therapeutics Inc880.99M
NRIXNurix Therapeutics Inc1.78B
KYMRKymera Therapeutics Inc11.51B
BDTXBlack Diamond Therapeutics Inc92.50M
IDYAIdeaya Biosciences Inc3.16B
ZNTLZentalis Pharmaceuticals Inc185.72M
ALXOAlx Oncology Holdings Inc154.87M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
OMFSInvesco Russell 2000 Dynamic Multifactor ETFAUM: 263.85M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-090.800-0.2360.80883.547.109
2026Q22026-08-06-0.100-0.245-0.10216.096.8110
2026Q12026-05-07-0.290-0.305-0.2863.277.9410
2025Q42026-03-11-0.350-0.264-0.3829.2510.1510
2025Q32025-11-05-0.250-0.333-0.2518.156.197
2025Q22025-08-05-0.280-0.351-0.2857.565.917
2025Q12025-05-14-0.300-0.309-0.3005.956.137
2024Q42025-03-06-0.230-0.313-0.3512.867.207
2024Q32024-11-04-0.310-0.430-0.3057.806.345
2024Q22024-08-08-0.450-0.638-0.4466.896.044
2024Q12024-05-06-0.590-0.633-0.5905.056.914
2023Q42024-03-07-0.570-0.744-0.5705.774.545
2023Q32023-11-02-0.340-0.700-0.34117.484.584
2023Q22023-08-04-0.700-0.710-0.7055.606.324
2023Q12023-05-08-0.730-0.708-0.7295.315.044
2022Q42023-03-09-0.690-0.594-0.6914.148.485

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-5.395-4.195-1.8700.420.69
2021FY-2.642-2.604-2.7261.321.32
2022FY-2.620-2.387-2.61819.2022.92
2023FY-2.340-2.415-2.34534.1632.43
2024FY-1.580-1.543-1.57822.6029.53
2025FY-1.180-1.107-1.18030.9131.83
2026FY--0.082--95.94
2027FY--0.988--0.29
2028FY--0.927--11.40
2029FY--0.907--22.93
2030FY--0.908--81.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-099081.560.007.00
2026Q4S2026-11-089063.340.0012.48
2026Q4S2026-10-299073.340.0012.48
2026Q4S2026-10-2010073.000.0012.48
2026Q4S2026-10-0110083.000.0012.48
2026Q4S2026-09-3010083.000.0012.48
2026Q4S2026-09-1110027.510.0012.48
2026Q4S2026-08-2510037.510.0012.48
2026Q4S2026-08-069027.570.0012.48
2026Q4S2026-07-298007.310.0012.48
2026Q4S2026-07-219007.490.0012.48
2026Q4S2026-07-179017.490.0012.48
2026Q4S2026-05-309017.490.0012.48
2026Q4S2026-05-2610018.000.0012.50

Estimate history

EPS, annual-0.715-1.389-1.87-2.726-2.618-2.345-1.578-1.180.0311
Period20182019202020212022202320242025TTM
EPS, quarterly-0.305-0.351-0.3-0.285-0.251-0.382-0.286-0.1020.801
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000.431.31919.22834.15522.60230.909112.13
Period20182019202020212022202320242025TTM
Sales, quarterly7.8082.8565.9527.5578.1539.2473.26716.07283.543
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual36.8236.8236.79141.341.80342.28255.59456.65759.963
Period20182019202020212022202320242025MRQ
Shares, quarterly55.59355.59455.72155.80356.54356.65758.7158.71459.963
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue112.1330.9122.6034.1619.231.320.430.000.00
Cost of Goods Sold Incl. D&A1.443.333.128.667.907.511.331.790.38
Gross Profit110.6927.5819.4825.4911.33-6.20-0.90-1.79-0.38
Selling, General and Administrative Excl. Other101.75109.68119.77133.40128.4694.5467.6349.2925.67
Research and Development76.2282.1391.41106.24102.3077.1056.3944.3621.23
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income8.94-82.11-100.28-107.91-117.14-100.73-68.53-51.08-26.05
Interest Expense0.000.000.000.000.001.910.980.540.37
Unusual Expense8.195.912.400.000.001.230.29-0.000.03
Net Income Before Taxes9.42-74.28-86.62-94.20-108.88-101.32-68.80-51.13-26.34
Income Taxes0.000.000.004.230.000.000.000.000.00
Consolidated Net Income9.42-74.28-86.62-98.43-108.88-101.32-68.80-51.13-26.34
Net Income From Continuing Operations9.42-74.28-86.62-98.43-108.88-101.32-68.80-51.13-26.34
Net Income9.42-74.28-86.62-98.43-108.88-101.32-68.80-51.13-26.34
EPS (Recurring)0.21-1.11-1.55-2.34-2.62-2.70-1.86-1.39-0.71
EPS (Basic, Before Extraordinaries)0.04-1.18-1.58-2.34-2.62-2.73-1.87-1.39-0.72
EPS (Diluted)0.03-1.18-1.58-2.34-2.62-2.73-1.87-1.39-0.72
EBITDA10.38-78.78-97.17-99.25-109.24-93.22-67.20-49.29-25.67
Non-Operating Income (Expense)8.6713.7416.0613.718.262.551.000.490.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.6910.4011.8912.7914.348.382.961.690.73
Price To Earnings Ratio61.0961.09-------
Price To Sales Ratio2.3111.0011.467.9313.80644.511,734.31--
Gross Margin98.7289.2286.2074.6458.91-469.75-208.60--
Operating Margin7.97-265.64-443.70-315.93-609.20-7,637.15-15,937.44--
Net Margin8.40-240.33-383.24-288.17-566.27-7,681.58-16,000.00--
Shares Outstanding59.9656.6655.5942.2841.8041.3036.7936.8236.82
Market Capitalization112.83112.83262.40272.30266.70848.32725.94762.47-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue83.5416.073.279.258.157.565.952.86
Cost of Goods Sold Incl. D&A0.200.200.240.800.900.900.830.76
Gross Profit83.3415.873.038.457.256.665.122.10
Selling, General and Administrative Excl. Other24.4324.6824.6028.0425.7527.7528.0426.10
Research and Development18.6418.3218.0221.2419.1020.8920.8019.75
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income58.91-8.80-21.57-19.60-18.50-21.10-22.91-24.00
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense2.270.000.005.910.000.000.000.00
Net Income Before Taxes58.15-7.19-19.88-21.66-15.85-17.94-18.83-19.50
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income58.15-7.19-19.88-21.66-15.85-17.94-18.83-19.50
Net Income From Continuing Operations58.15-7.19-19.88-21.66-15.85-17.94-18.83-19.50
Net Income58.15-7.19-19.88-21.66-15.85-17.94-18.83-19.50
EPS (Recurring)0.82-0.10-0.29-0.31-0.25-0.28-0.30-0.35
EPS (Basic, Before Extraordinaries)0.81-0.10-0.29-0.38-0.25-0.28-0.30-0.35
EPS (Diluted)0.80-0.10-0.29-0.38-0.25-0.28-0.30-0.35
EBITDA59.11-8.61-21.34-18.79-17.60-20.20-22.09-23.24
Non-Operating Income (Expense)1.511.611.703.852.653.164.084.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.522.552.382.242.732.732.692.48
Price To Earnings Ratio61.09-------
Price To Sales Ratio2.319.3811.789.9012.5712.249.7611.61
Gross Margin99.7698.7692.7291.3388.9688.0986.1173.35
Operating Margin70.52-54.78-660.33-211.92-226.92-279.17-384.96-840.51
Net Margin69.60-44.74-608.36-234.28-194.39-237.34-316.43-682.88
Shares Outstanding59.9658.7158.7156.6656.5455.8055.7255.59
Market Capitalization112.83286.52280.59305.38276.43261.98202.98262.40

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments160.14243.75234.06345.80154.29185.7715.5240.02
Short Term Receivables0.000.000.000.00300.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets3.095.856.125.605.274.921.360.38
Total Current Assets163.24249.60240.18351.40459.56190.6916.8940.40
Net Property, Plant & Equipment32.8632.6042.9149.4056.0862.333.712.09
Total Investments and Advances2.001.711.711.711.731.731.730.57
Intangible Assets-------0.00
Deferred Tax Assets196.56174.39------
Other Assets0.000.071.112.382.400.840.010.00
Total Assets394.66458.37285.92404.88519.77255.5922.3443.06
Short Term Debt Incl. Current Port. of LT Debt0.929.078.525.976.993.985.510.00
Accounts Payable4.273.796.265.413.823.683.442.01
Income Tax Payable-0.000.67-----
Other Current Liabilities54.5554.1442.9843.8237.8811.193.701.45
Total Current Liabilities59.7466.9958.4455.2048.6918.8512.653.46
Long Term Debt40.3528.0636.5545.5451.3478.0297.6678.28
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities196.56174.39------
Other Liabilities206.52234.46268.12304.03322.8712.550.040.59
Total Liabilities503.16503.90363.11404.77422.90109.41110.3682.33
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity-108.50-45.53-77.190.1196.87146.19-88.02-39.27
Total Shareholders Equity-108.50-45.53-77.190.1196.87146.19-88.02-39.27
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-108.50-45.53-77.190.1196.87146.19-88.02-39.27
Total Liabilities & Stockholders Equity394.66458.37285.92404.88519.77255.5922.3443.06
Book Value Per Share-1.92-0.82-1.830.002.353.97-2.39-1.07
Tangible Book Value Per Share-1.92-0.82-1.830.002.353.97-2.39-1.07
Full-Time Employees1061121161611199585-
Price to Book Ratio-8.09-9.28-4.7410.969.755.10-5.72-
Return on Assets-17.42-23.28-28.50-23.55-26.13-49.51-156.35-
Return on Equity----224.54-83.37-236.54--
Return on Invested Capital----238.52-68.36-30.69-530.10-67.52
Quick Ratio2.733.734.116.379.4410.121.3311.68
Current Ratio2.733.734.116.379.4410.121.3311.68

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income9.42-74.28-86.62-98.43-108.88-101.32-68.80-51.13-26.34
Depreciation1.493.333.128.667.907.511.331.790.38
Other Funds (Non Cash)14.2616.9915.3613.5413.0510.117.481.800.89
Funds from Operations25.16-53.96-68.14-76.23-87.93-83.69-59.99-47.53-25.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-108.78-32.14-32.27-41.88281.5533.4428.701.202.42
Cash from Operating Activities-83.62-86.10-100.41-118.11193.61-50.25-31.29-46.34-22.65
Capital Expenditures-0.06-0.05-0.91-1.22-1.21-3.31-16.18-0.97-1.54
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.250.000.00
Purchase or Sale of Investments16.79112.09-29.00145.67-243.1139.49-92.980.000.00
Purchase of Investments-151.61-131.25-261.47-73.90-409.35-99.98-92.980.000.00
Sale Or Maturity of Investments168.40243.34232.47219.57166.23139.470.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities16.73112.04-29.90144.45-244.3236.17-108.91-0.96-1.54
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock56.611.02106.011.781.7643.62213.2015.9840.63
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock56.611.02106.011.781.7643.62213.2015.9840.63
Proceedsfrom Stock Options-0.350.00103.400.000.0042.20211.9815.9840.63
Issuance or Reduction of Debt, Net0.000.000.000.000.00-21.204.277.9811.14
Change in Long Term Debt0.000.000.000.000.00-21.204.277.9811.14
Issuance of Long Term Debt0.000.000.000.000.000.0019.807.9811.96
Reduction of Long Term Debt0.000.000.000.000.00-21.20-15.530.00-0.82
Net Financing Active Other Cash Flow0.000.00-0.580.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-0.580.000.000.000.000.000.00
Cash from Financing Activities56.611.02105.431.781.7622.42217.4723.9751.77
Net Change in Cash-10.2826.96-24.8828.12-48.958.3477.27-23.3327.58
Free Cash Flow-83.68-86.15-101.31-119.33192.40-53.56-47.47-47.30-24.19
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----1.38----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments156.22167.58184.88160.14181.53199.91
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.092.463.183.092.593.93
Total Current Assets158.31170.05188.06163.24184.12203.84
Net Property, Plant & Equipment30.6231.3432.1032.8618.8420.39
Total Investments and Advances2.002.002.002.002.002.00
Deferred Tax Assets---196.56--
Other Assets0.020.000.000.000.010.01
Total Assets190.95203.39222.17394.66204.96226.24
Short Term Debt Incl. Current Port. of LT Debt3.792.821.860.926.756.18
Accounts Payable2.173.213.324.273.213.32
Other Current Liabilities31.3544.5559.2254.5575.1268.29
Total Current Liabilities37.3150.5864.4059.7485.0977.79
Long Term Debt40.0840.2840.1340.3515.7717.52
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---196.56--
Other Liabilities127.64193.57194.04206.52193.76207.59
Total Liabilities205.04284.43298.57503.16294.62302.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-14.08-81.04-76.41-108.50-89.66-76.66
Total Shareholders Equity-14.08-81.04-76.41-108.50-89.66-76.66
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-14.08-81.04-76.41-108.50-89.66-76.66
Total Liabilities & Stockholders Equity190.95203.39222.17394.66204.96226.24
Book Value Per Share-0.23-1.38-1.30-1.92-1.59-1.37
Tangible Book Value Per Share-0.23-1.38-1.30-1.92-1.59-1.37
Full-Time Employees---106--
Price to Book Ratio-8.09-3.75-2.50-3.41-3.56-4.25
Return on Assets4.76-30.06-31.33-17.42-28.10-27.18
Return on Invested Capital223.72-----
Quick Ratio4.243.362.922.732.162.62
Current Ratio4.243.362.922.732.162.62

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income58.15-7.19-19.88-21.66-15.85-17.94
Depreciation0.210.230.240.800.850.85
Other Funds (Non Cash)2.442.472.566.793.073.81
Funds from Operations60.80-4.49-17.08-14.07-11.92-13.28
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-79.04-13.36-8.19-8.20-6.94-7.72
Cash from Operating Activities-18.24-17.84-25.27-22.27-18.86-21.00
Capital Expenditures-0.01-0.050.000.000.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments24.20-2.92-17.7213.2335.5733.86
Purchase of Investments-13.60-37.08-66.94-33.98-4.00-42.14
Sale Or Maturity of Investments37.8034.1749.2247.2139.5876.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities24.19-2.97-17.7213.2335.5733.83
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.28-0.0249.770.580.050.25
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.28-0.0249.770.580.050.25
Proceedsfrom Stock Options0.00-0.03-0.320.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities6.28-0.0249.770.580.050.25
Net Change in Cash12.22-20.836.79-8.4616.7613.09
Free Cash Flow-18.25-17.89-25.27-22.27-18.86-21.02

Revenue breakdown

Pharmaceutical Preparations2024: 22.60M 2025: 30.91M
United States2024: 22.60M 2025: 30.91M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.12%2.3M31.6M719.91K
2026-10-157.76%2.5M31.6M658.04K
2026-09-306.88%2.2M31.3M378.98K
2026-09-156.37%2.0M31.3M341.62K
2026-08-316.29%2.0M31.3M304.21K
2026-08-145.71%1.8M31.3M264.11K
2026-07-315.12%1.6M31.3M244.65K
2026-07-154.96%1.5M31.0M228.06K
2026-06-305.15%1.6M31.0M168.67K
2026-06-154.50%1.4M31.0M154.24K
2026-05-294.76%1.5M31.0M159.38K
2026-05-157.34%1.3M18.3M149.47K
2026-04-304.28%1.4M31.8M152.00K
2026-04-154.66%1.4M29.5M162.46K
2026-03-314.50%1.3M29.5M176.65K
2026-03-134.35%1.3M29.5M175.39K
2026-02-274.00%1.2M29.5M163.95K
2026-02-133.93%1.2M29.5M184.64K
2026-01-304.26%1.2M28.3M195.81K
2026-01-154.16%1.2M28.3M221.75K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.031.6762320.000.195-0.0070.001
call5.000.000.050.003.9210.000.000.110-0.0120.001
call7.500.004.900.455.0276.000.000.094-0.0140.001
put2.500.051.502.500.0005300.00-0.777-0.0070.001
put5.000.805.502.000.0000.000.00-0.892-0.0120.001
put7.503.108.000.000.0000.000.00-0.909-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-053Initial statement of beneficial ownership of securities2026-10-01SEC
2026-10-05SCHEDULE 13G/ASEC
2026-10-018-KCurrent report2026-09-25SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-04-218-KCurrent report2026-04-21SEC
2026-04-134Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-03-26S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-1110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-118-KCurrent report2026-03-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Flagship Pioneering, LLC21.59%
BVF INC/IL9.95%
FMR LLC9.34%
DEERFIELD MANAGEMENT COMPANY, L.P.7.48%
BlackRock, Inc.4.47%
RAYMOND JAMES FINANCIAL INC4.24%
Euclidean Capital LLC2.68%
VANGUARD CAPITAL MANAGEMENT LLC2.55%
GEODE CAPITAL MANAGEMENT, LLC1.45%
Siren, L.L.C.1.23%

Funds

Fund% owned
Fidelity Growth Company Fund3.09%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.75%
iShares Russell 2000 ETF1.53%
Fidelity Growth Company K6 Fund0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.73%
Fidelity Small Cap Index Fund0.68%
Select Biotechnology Portfolio0.63%
iShares Russell 2000 Growth ETF0.58%
Fidelity Series Growth Company Fund0.45%
iShares Biotechnology ETF0.38%

OakChart. FHTX. Cached 15 minutes.

Some panels did not load: insider.